Inactive Instrument

MannKind Corporation Stock Nasdaq

Equities

US56400P2011

Biotechnology & Medical Research

End-of-day quote Nasdaq
- USD - Intraday chart for MannKind Corporation
Sales 2024 * 260M Sales 2025 * 313M Capitalization 1.11B
Net income 2024 * 38M Net income 2025 * 73M EV / Sales 2024 * 3.32 x
Net cash position 2024 * 248M Net cash position 2025 * 273M EV / Sales 2025 * 2.68 x
P/E ratio 2024 *
31.1 x
P/E ratio 2025 *
18 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.47%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 47 16-03-13
Director of Finance/CFO 61 17-07-16
Chief Tech/Sci/R&D Officer 57 22-09-30
Members of the board TitleAgeSince
Director/Board Member 55 18-11-26
Director/Board Member 69 19-12-31
Director/Board Member 80 03-09-30
More insiders
MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Related indices
More about the company